Industry Research Reports
Global Raibizumab Biosimilars Market Research Report 2024
Industry: Pharma & Healthcare
Published Date: 2024-01-20
Pages: 112 Pages
Report ld: 2755748
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
The global Raibizumab Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Raibizumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Raibizumab Biosimilars.
MARKET SEGMENTATION
By Company
- Roche
- Novartis
- Genentech
- Pfizer
- Sartorius
- Eli Lilly
- Bayer
- Amgen
- PlantForm
- PharmaPraxis
- Samsung Bioepis
- Centus
- Cadila Pharmaceuticals
- Dr Reddy's
- Aurobindo Pharma
- Biocad
- MAbxience
- Hetero
- Biocon
- Kirin Biologics
- Mylan
- BeiGene
- Innovent
- Qilu Pharmaceutical
- Hengrui Pharmaceuticals
- Hisun Pharmaceutical
- TOT BIOPHARM
- Luye Pharmaceutical
- Henlius
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- AMD
- CNV
- DME
Segment by Application
- ARMD
- Diabetic Retinopathy
- Macular Edema
REPORT SCOPE
The Raibizumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Raibizumab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Raibizumab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Raibizumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Raibizumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Raibizumab Biosimilars Market Overview
1.1 Product Overview and Scope of Raibizumab Biosimilars
1.2 Raibizumab Biosimilars Segment by Type
1.2.1 Global Raibizumab Biosimilars Market Value Comparison by Type (2024-2030)
1.2.2 AMD
1.2.3 CNV
1.2.4 DME
1.3 Raibizumab Biosimilars Segment by Application
1.3.1 Global Raibizumab Biosimilars Market Value by Application: (2024-2030)
1.3.2 ARMD
1.3.3 Diabetic Retinopathy
1.3.4 Macular Edema
1.4 Global Raibizumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Raibizumab Biosimilars Revenue 2019-2030
1.4.2 Global Raibizumab Biosimilars Sales 2019-2030
1.4.3 Global Raibizumab Biosimilars Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Raibizumab Biosimilars Market Competition by Manufacturers
2.1 Global Raibizumab Biosimilars Sales Market Share by Manufacturers (2019-2024)
2.2 Global Raibizumab Biosimilars Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Raibizumab Biosimilars Average Price by Manufacturers (2019-2024)
2.4 Global Raibizumab Biosimilars Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Raibizumab Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Raibizumab Biosimilars, Product Type & Application
2.7 Raibizumab Biosimilars Market Competitive Situation and Trends
2.7.1 Raibizumab Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Raibizumab Biosimilars Players Market Share by Revenue
2.7.3 Global Raibizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Raibizumab Biosimilars Retrospective Market Scenario by Region
3.1 Global Raibizumab Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Raibizumab Biosimilars Global Raibizumab Biosimilars Sales by Region: 2019-2030
3.2.1 Global Raibizumab Biosimilars Sales by Region: 2019-2024
3.2.2 Global Raibizumab Biosimilars Sales by Region: 2025-2030
3.3 Global Raibizumab Biosimilars Global Raibizumab Biosimilars Revenue by Region: 2019-2030
3.3.1 Global Raibizumab Biosimilars Revenue by Region: 2019-2024
3.3.2 Global Raibizumab Biosimilars Revenue by Region: 2025-2030
3.4 North America Raibizumab Biosimilars Market Facts & Figures by Country
3.4.1 North America Raibizumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Raibizumab Biosimilars Sales by Country (2019-2030)
3.4.3 North America Raibizumab Biosimilars Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Raibizumab Biosimilars Market Facts & Figures by Country
3.5.1 Europe Raibizumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Raibizumab Biosimilars Sales by Country (2019-2030)
3.5.3 Europe Raibizumab Biosimilars Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Raibizumab Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Raibizumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Raibizumab Biosimilars Sales by Country (2019-2030)
3.6.3 Asia Pacific Raibizumab Biosimilars Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Raibizumab Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Raibizumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Raibizumab Biosimilars Sales by Country (2019-2030)
3.7.3 Latin America Raibizumab Biosimilars Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Raibizumab Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Raibizumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Raibizumab Biosimilars Sales by Country (2019-2030)
3.8.3 Middle East and Africa Raibizumab Biosimilars Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Raibizumab Biosimilars Sales by Type (2019-2030)
4.1.1 Global Raibizumab Biosimilars Sales by Type (2019-2024)
4.1.2 Global Raibizumab Biosimilars Sales by Type (2025-2030)
4.1.3 Global Raibizumab Biosimilars Sales Market Share by Type (2019-2030)
4.2 Global Raibizumab Biosimilars Revenue by Type (2019-2030)
4.2.1 Global Raibizumab Biosimilars Revenue by Type (2019-2024)
4.2.2 Global Raibizumab Biosimilars Revenue by Type (2025-2030)
4.2.3 Global Raibizumab Biosimilars Revenue Market Share by Type (2019-2030)
4.3 Global Raibizumab Biosimilars Price by Type (2019-2030)
5 Segment by Application
5.1 Global Raibizumab Biosimilars Sales by Application (2019-2030)
5.1.1 Global Raibizumab Biosimilars Sales by Application (2019-2024)
5.1.2 Global Raibizumab Biosimilars Sales by Application (2025-2030)
5.1.3 Global Raibizumab Biosimilars Sales Market Share by Application (2019-2030)
5.2 Global Raibizumab Biosimilars Revenue by Application (2019-2030)
5.2.1 Global Raibizumab Biosimilars Revenue by Application (2019-2024)
5.2.2 Global Raibizumab Biosimilars Revenue by Application (2025-2030)
5.2.3 Global Raibizumab Biosimilars Revenue Market Share by Application (2019-2030)
5.3 Global Raibizumab Biosimilars Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Raibizumab Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Raibizumab Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Genentech
6.3.1 Genentech Corporation Information
6.3.2 Genentech Description and Business Overview
6.3.3 Genentech Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Genentech Raibizumab Biosimilars Product Portfolio
6.3.5 Genentech Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Raibizumab Biosimilars Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Sartorius
6.5.1 Sartorius Corporation Information
6.5.2 Sartorius Description and Business Overview
6.5.3 Sartorius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sartorius Raibizumab Biosimilars Product Portfolio
6.5.5 Sartorius Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Eli Lilly Raibizumab Biosimilars Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bayer Raibizumab Biosimilars Product Portfolio
6.7.5 Bayer Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Amgen Raibizumab Biosimilars Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 PlantForm
6.9.1 PlantForm Corporation Information
6.9.2 PlantForm Description and Business Overview
6.9.3 PlantForm Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 PlantForm Raibizumab Biosimilars Product Portfolio
6.9.5 PlantForm Recent Developments/Updates
6.10 PharmaPraxis
6.10.1 PharmaPraxis Corporation Information
6.10.2 PharmaPraxis Description and Business Overview
6.10.3 PharmaPraxis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 PharmaPraxis Raibizumab Biosimilars Product Portfolio
6.10.5 PharmaPraxis Recent Developments/Updates
6.11 Samsung Bioepis
6.11.1 Samsung Bioepis Corporation Information
6.11.2 Samsung Bioepis Raibizumab Biosimilars Description and Business Overview
6.11.3 Samsung Bioepis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Samsung Bioepis Raibizumab Biosimilars Product Portfolio
6.11.5 Samsung Bioepis Recent Developments/Updates
6.12 Centus
6.12.1 Centus Corporation Information
6.12.2 Centus Raibizumab Biosimilars Description and Business Overview
6.12.3 Centus Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Centus Raibizumab Biosimilars Product Portfolio
6.12.5 Centus Recent Developments/Updates
6.13 Cadila Pharmaceuticals
6.13.1 Cadila Pharmaceuticals Corporation Information
6.13.2 Cadila Pharmaceuticals Raibizumab Biosimilars Description and Business Overview
6.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Product Portfolio
6.13.5 Cadila Pharmaceuticals Recent Developments/Updates
6.14 Dr Reddy's
6.14.1 Dr Reddy's Corporation Information
6.14.2 Dr Reddy's Raibizumab Biosimilars Description and Business Overview
6.14.3 Dr Reddy's Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Dr Reddy's Raibizumab Biosimilars Product Portfolio
6.14.5 Dr Reddy's Recent Developments/Updates
6.15 Aurobindo Pharma
6.15.1 Aurobindo Pharma Corporation Information
6.15.2 Aurobindo Pharma Raibizumab Biosimilars Description and Business Overview
6.15.3 Aurobindo Pharma Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Aurobindo Pharma Raibizumab Biosimilars Product Portfolio
6.15.5 Aurobindo Pharma Recent Developments/Updates
6.16 Biocad
6.16.1 Biocad Corporation Information
6.16.2 Biocad Raibizumab Biosimilars Description and Business Overview
6.16.3 Biocad Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Biocad Raibizumab Biosimilars Product Portfolio
6.16.5 Biocad Recent Developments/Updates
6.17 MAbxience
6.17.1 MAbxience Corporation Information
6.17.2 MAbxience Raibizumab Biosimilars Description and Business Overview
6.17.3 MAbxience Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.17.4 MAbxience Raibizumab Biosimilars Product Portfolio
6.17.5 MAbxience Recent Developments/Updates
6.18 Hetero
6.18.1 Hetero Corporation Information
6.18.2 Hetero Raibizumab Biosimilars Description and Business Overview
6.18.3 Hetero Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Hetero Raibizumab Biosimilars Product Portfolio
6.18.5 Hetero Recent Developments/Updates
6.19 Biocon
6.19.1 Biocon Corporation Information
6.19.2 Biocon Raibizumab Biosimilars Description and Business Overview
6.19.3 Biocon Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Biocon Raibizumab Biosimilars Product Portfolio
6.19.5 Biocon Recent Developments/Updates
6.20 Kirin Biologics
6.20.1 Kirin Biologics Corporation Information
6.20.2 Kirin Biologics Raibizumab Biosimilars Description and Business Overview
6.20.3 Kirin Biologics Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Kirin Biologics Raibizumab Biosimilars Product Portfolio
6.20.5 Kirin Biologics Recent Developments/Updates
6.21 Mylan
6.21.1 Mylan Corporation Information
6.21.2 Mylan Raibizumab Biosimilars Description and Business Overview
6.21.3 Mylan Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Mylan Raibizumab Biosimilars Product Portfolio
6.21.5 Mylan Recent Developments/Updates
6.22 BeiGene
6.22.1 BeiGene Corporation Information
6.22.2 BeiGene Raibizumab Biosimilars Description and Business Overview
6.22.3 BeiGene Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.22.4 BeiGene Raibizumab Biosimilars Product Portfolio
6.22.5 BeiGene Recent Developments/Updates
6.23 Innovent
6.23.1 Innovent Corporation Information
6.23.2 Innovent Raibizumab Biosimilars Description and Business Overview
6.23.3 Innovent Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Innovent Raibizumab Biosimilars Product Portfolio
6.23.5 Innovent Recent Developments/Updates
6.24 Qilu Pharmaceutical
6.24.1 Qilu Pharmaceutical Corporation Information
6.24.2 Qilu Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.24.5 Qilu Pharmaceutical Recent Developments/Updates
6.25 Hengrui Pharmaceuticals
6.25.1 Hengrui Pharmaceuticals Corporation Information
6.25.2 Hengrui Pharmaceuticals Raibizumab Biosimilars Description and Business Overview
6.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Product Portfolio
6.25.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.26 Hisun Pharmaceutical
6.26.1 Hisun Pharmaceutical Corporation Information
6.26.2 Hisun Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.26.5 Hisun Pharmaceutical Recent Developments/Updates
6.27 TOT BIOPHARM
6.27.1 TOT BIOPHARM Corporation Information
6.27.2 TOT BIOPHARM Raibizumab Biosimilars Description and Business Overview
6.27.3 TOT BIOPHARM Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.27.4 TOT BIOPHARM Raibizumab Biosimilars Product Portfolio
6.27.5 TOT BIOPHARM Recent Developments/Updates
6.28 Luye Pharmaceutical
6.28.1 Luye Pharmaceutical Corporation Information
6.28.2 Luye Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.28.3 Luye Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.28.4 Luye Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.28.5 Luye Pharmaceutical Recent Developments/Updates
6.29 Henlius
6.29.1 Henlius Corporation Information
6.29.2 Henlius Raibizumab Biosimilars Description and Business Overview
6.29.3 Henlius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.29.4 Henlius Raibizumab Biosimilars Product Portfolio
6.29.5 Henlius Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Raibizumab Biosimilars Industry Chain Analysis
7.2 Raibizumab Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Raibizumab Biosimilars Production Mode & Process
7.4 Raibizumab Biosimilars Sales and Marketing
7.4.1 Raibizumab Biosimilars Sales Channels
7.4.2 Raibizumab Biosimilars Distributors
7.5 Raibizumab Biosimilars Customers
8 Raibizumab Biosimilars Market Dynamics
8.1 Raibizumab Biosimilars Industry Trends
8.2 Raibizumab Biosimilars Market Drivers
8.3 Raibizumab Biosimilars Market Challenges
8.4 Raibizumab Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
Raibizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Raibizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 181
USD 3950.00
(Single User License)
Global Raibizumab Biosimilars Market Research Report 2025
The global market for Raibizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 126
USD 2900.00
(Single User License)
Raibizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Published Date: 2024-01-11
Pages: 165
USD 3950.00
(Single User License)
Raibizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Raibizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 181
USD 3950.00 (Single User License)Global Raibizumab Biosimilars Market Research Report 2025
The global market for Raibizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 126
USD 2900.00 (Single User License)Raibizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Published: 2024-01-11
Pages: 165
USD 3950.00 (Single User License)
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
REPORT SCOPE
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now